Vistra Corp vs Zimmer Biomet Holdings Inc — how do they compare? Vistra Corp trades at $151.58 (market cap $50.11B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Vistra Corp is far larger — about 2.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| VST | ZBH | |
|---|---|---|
Market Cap | $50.11B | $17.97B |
Sector | Technology | Health |
52-Week High | $217.92 | $104.26 |
52-Week Low | $134.71 | $79.58 |
Enterprise Value | $72.05B | $25.04B |
Dividend Yield | 0.62% | 1.02% |
Signals from Pluang's Aura AI — not financial advice
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical signal and strong analyst support. The stock shows mixed quarterly earnings but projects significant revenue and net income growth into 2026. Recent news highlights CEO and institutional buying, long-term power agreements with tech giants, and a consensus price target of $228.40, suggesting substantial upside potential from current levels.
The outlook is positive, driven by robust power demand, strategic partnerships, and a diversified generation fleet. Key risks include regulatory uncertainty and earnings volatility. With 91% of analysts rating it a buy and insider confidence, VST presents a compelling opportunity for growth-oriented investors, though market fluctuations and execution risks warrant caution.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Trailing returns across standard periods
Latest headlines on both assets
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →